Effect of anlotinib as a third- or further-line therapy in advanced non-small cell lung cancer patients with different histologic types: Subgroup analysis in the ALTER0303 trial.,Cancer Medicine

当前位置： X-MOL 学术 › Cancer Med. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Effect of anlotinib as a third- or further-line therapy in advanced non-small cell lung cancer patients with different histologic types: Subgroup analysis in the ALTER0303 trial.
Cancer Medicine ( IF 2.9 ) Pub Date : 2020-02-16 , DOI: 10.1002/cam4.2913
Ying Cheng ₁ , Baohui Han ₂ , Kai Li ₃ , Qiming Wang ₄ , Li Zhang ₅ , Jianhua Shi ₆ , Zhehai Wang ₇ , Jianxing He ₈ , Yuankai Shi ₉ , Weiqiang Chen ₁₀ , Xiuwen Wang ₁₁ , Yi Luo ₁₂ , Kejun Nan ₁₃ , Faguang Jin ₁₄ , Baolan Li ₁₅ , Jing Zhu ₁₆

Affiliation

Jilin Cancer Hospital, Changchun, China.
Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China.
Tianjin Medical University Cancer Hospital, Tianjin, China.
Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China.
Peking Union Medical College Hospital, Beijing, China.
Lin Yi Cancer Hospital, Linyi, China.
Shandong Cancer Hospital, Jinan, China.
The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China.
Lanzhou Military General Hospital, Lanzhou, China.
Qilu Hospital of Shandong University, Jinan, China.
Hunan Cancer Hospital, Changsha, China.
The First Affiliated Hospital of Xi'An Jiaotong University, Xi'an, China.
Tang Du Hospital, Xi'an, China.
Beijing Chest Hospital, Capital Medical University, Beijing, China.
Jilin Cancer Hospital, Jilin, China.

BACKGROUND Anlotinib showed significant survival benefits in advanced non-small cell lung cancer (NSCLC) patients as a third- or further-line treatment in the ALTER0303 trial. We aimed to evaluate the efficacy of anlotinib in patients with different histologies. METHODS The ALTER0303 trial was a randomized, open-label, phase 3 study of anlotinib in NSCLC patients previously treated with at least two lines of chemotherapy or a tyrosine kinase inhibitor (TKI) in 31 centers in China. Patients were randomly assigned at a 2:1 ratio to receive anlotinib (12 mg QD from days 1 to 14 of a 21-day cycle) or placebo until progression or intolerable toxicity. The primary endpoint was overall survival (OS). We assessed the efficacy of anlotinib in histological subgroups in the full analysis set. RESULTS In the ALTER0303 trial, 336 patients had the histological subtype of adenocarcinoma (ACC), 86 patients had the histological subtype of squamous cell carcinoma (SCC), and 15 patients had another subtype. In the ACC subgroup, the median OS time was significantly improved with anlotinib compared with placebo (9.6 months vs 6.9 months, P = .0051), as was the median progression-free survival (PFS) time (5.5 months vs 1.4 months, P < .0001). In the SCC subgroup, the median OS time was 10.7 months in the anlotinib group and 6.5 months in the placebo group (P = .2570), and the median PFS time was 4.8 months and 2.7 months (P = .0004), respectively. The common adverse events observed in the SCC and ACC subgroups were similar. CONCLUSIONS Our findings suggest that anlotinib significantly improves PFS and OS in ACC patients and has a tendency to prolong survival in SCC patients.

更新日期：2020-02-16

点击分享查看原文

点击收藏

公开下载

阅读更多本刊新发论文本刊介绍/投稿指南